Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.

Journal of medical case reports - 23 Apr 2021

Montero-Macias Rosa, Koual Meriem, Crespel Céline, Le Frére-Belda Marie Aude, Hélène Hélène Blons, Nguyen-Xuan Huyen-Thu, Garinet Simon, Perkins Géraldine, Balay Vincent, Durdux Catherine, Florin Marie, Péré Hélène, Bats Anne-Sophie

Abstract excerpt

BACKGROUND: Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer. CASE PRESENTATION: Here we present the case of a patient with cervical cancer treated in this setting. A 49-year-old woman...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33888155
DOI: 10.1186/s13256-021-02767-9
PMCID: PMC8063354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.PMID 33888155Read ↗

Case report: Response with chemotherapy and Olaparib in a patient with advanced cervical adenocarcinomaSemantic proximity Read ↗

Leveraging DNA repair deficiency in gynecologic oncology.Semantic proximity Read ↗

Poly (ADP-Ribose) polymerase inhibitors have efficacy in a fraction of platinum-resistant ovarian cancer patientsSemantic proximity Read ↗

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.Semantic proximity Read ↗

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitorSemantic proximity Read ↗

Major clinical research advances in gynecologic cancer in 2017.Semantic proximity Read ↗

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.Semantic proximity Read ↗

Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer modelSemantic proximity Read ↗

Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report.Semantic proximity Read ↗

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.Semantic proximity Read ↗

An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.Semantic proximity Read ↗

Recurrent Ovarian Cancer in BRCAness Phenotype: A Treatment ChallengeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.